Novartis' Sandoz strikes at Roche with first US generic of blockbuster Esbriet

Despite an ongoing strategic review that might alter Sandoz’s future, the Novartis generics engine keeps churning out new products.

Sandoz has launched the first fully substitutable U.S. generic of Roche’s blockbuster idiopathic pulmonary fibrosis (IPF) therapy Esbriet, the Novartis unit said Thursday.